The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
about
Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic DiseasesEpigenetic modulators as therapeutic targets in prostate cancerThe role of GATA2 in lethal prostate cancer aggressiveness.Curcumin sensitizes human gastric cancer cells to 5-fluorouracil through inhibition of the NFκB survival-signaling pathwayDietary Supplements Commonly Used by Cancer Survivors: Are There Any Benefits?Prevention and treatment of cancer targeting chronic inflammation: research progress, potential agents, clinical studies and mechanisms.Therapeutic potential of novel formulated forms of curcumin in the treatment of breast cancer by the targeting of cellular and physiological dysregulated pathways.Curcumin: A new candidate for melanoma therapy?Curcumin Enhances the Anticancer Effect Of 5-fluorouracil against Gastric Cancer through Down-Regulation of COX-2 and NF- κB Signaling Pathways.A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer.The combination of curcumin and 5-fluorouracil in cancer therapy.Modulation of AKR1C2 by Curcumin Decreases Testosterone Production in Prostate Cancer.Oligomeric proanthocyanidins (OPCs) target cancer stem-like cells and suppress tumor organoid formation in colorectal cancer.Curcumin-mediated regulation of intestinal barrier function: The mechanism underlying its beneficial effects.Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriers.Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways.Molecular Mechanisms Underlying Curcumin-Mediated Therapeutic Effects in Type 2 Diabetes and Cancer.Next-Gen Therapeutics for Skin Cancer: Nutraceuticals
P2860
Q28069705-F2379CBB-DE49-4365-8949-49646348EE7FQ28071912-3F5F390B-8967-41B5-8616-366CC1D6FAABQ33848134-9A2BC6E1-E371-437B-9212-6FE1D073DEDFQ37488862-9F33684D-F5F4-4FBB-B63C-96E5B52B3021Q38622264-F813BEAE-7461-4B9B-82EB-29FD7E3BECBCQ38668187-BCD1FF5F-FC56-4DCE-BCC8-FDAFCF4075C8Q38832201-2B859688-E7C0-4F0D-B7CC-E839C9E97012Q38859978-07C67D6C-B8CF-43CF-8C15-82B4ACB8D09EQ46083687-BCBDDDEF-6DE4-4C95-8175-D9CAADDCA742Q47126582-2097C115-A181-4634-AC63-3A4F4DF68B55Q47577912-8824C8F7-35D9-412F-8788-0607A64BD747Q49711327-71C0CD83-26DA-45A6-81EE-3669FBE16687Q49789755-DD339570-93F1-4DBA-AB06-F102E5ACCDF9Q50116101-1EA12A74-C2A4-4264-A09F-D98DE7616AD4Q50245206-36902C6A-FB43-4EB1-940D-F73FCD4F090EQ53076797-7D92F809-DA75-4813-9428-73F5D94CA62CQ55284911-950CC032-FE7F-4DEC-8BB0-80F6BC2EEF93Q57945048-6315F991-DAF9-4BFA-B57D-262389C22F74
P2860
The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
The New Combination Docetaxel, ...... ancer: A Pilot Phase II Study.
@en
type
label
The New Combination Docetaxel, ...... ancer: A Pilot Phase II Study.
@en
prefLabel
The New Combination Docetaxel, ...... ancer: A Pilot Phase II Study.
@en
P2093
P50
P356
P1433
P1476
The New Combination Docetaxel, ...... ancer: A Pilot Phase II Study.
@en
P2093
Eloise Planchat
Emilie Gadea
Hakim Mahammedi
Hervé Curé
Isabelle Van-Praagh
Jean-Christophe Eymard
Laurent Guy
Laurent Savareux
Marc Atger
Mathilde Bayet-Robert
P356
10.1159/000441148
P577
2016-01-16T00:00:00Z